Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Andrew J. Armstrong(Duke University), Daniel J. George(Duke University), Jason A. Somarelli(Duke Medical Center), Emmanuel S. Antonarakis(University of Minnesota), Ryan Dittamore(Epic Sciences (United States)), David M. Nanus(Cornell University), Monika Anand(Duke University), Gabor Kemeny(Duke University), Daniel C. Danila, Blair Thornburg(Duke University), Susan Halabi(Duke Medical Center), Changxue Lu(Johns Hopkins University), Patrick Healy(Duke University), John L. Silberstein(Johns Hopkins University), Giuseppe Galletti(Cornell University), Paraskevi Giannakakou(Cornell University), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Rhonda Wilder(Duke University), Jun Luo(Johns Hopkins University), Russell Z. Szmulewitz(University of Chicago), Julia Rasmussen(Duke University), Colin Rothwell(Duke University), Yan Chen(Johns Hopkins University), Santosh Gupta(Duke University), Simon G. Gregory(Center for Human Genetics), William R. Berry(Duke University), Scott T. Tagawa(Cornell University)
Cited by 364
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k